George Ng, the Chief Executive Officer of Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has recently acquired 87,200 shares of the company's common stock. According to InvestingPro data, this ...

Patrick Lin, Chief Business and Strategy Officer at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), recently acquired 43,500 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Processa ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) is projected to release its earnings data on Thursday, March 27th. Analysts expect Processa Pharmaceuticals to post earnings of ($0.76 ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...